Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal by unknown
Brown et al. Critical Care  (2016) 20:273 
DOI 10.1186/s13054-016-1422-2REVIEW Open AccessNonvitamin K antagonist oral anticoagulant
activity: challenges in measurement and
reversal
Karen S. Brown1, Hamim Zahir1, Michael A. Grosso1, Hans J. Lanz1, Michele F. Mercuri1 and Jerrold H. Levy2*Abstract
Background: Four nonvitamin K antagonist oral anticoagulants (NOACs) are approved for the prevention of stroke
in patients with nonvalvular atrial fibrillation and for the treatment of venous thromboembolism. These include the
direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban.
Bleeding is a complication for all anticoagulants and concerns regarding bleeding risk and the suitability of effective
reversal strategies may be a barrier to their prescription. Despite the reduced risk of bleeding compared with vitamin K
antagonists, questions persist regarding the management of bleeding related to NOAC use.
Main text: To date, although a number of assays are responsive to NOACs, no single routine laboratory test has been
identified to accurately measure the clinical anticoagulation state of patients on NOACs or established as a reliable
predictor of bleeding risk. In addition, the establishment of a reliable human bleeding model to test novel inhibitors of
the coagulation cascade has proved challenging. Although routine monitoring of anticoagulant levels is not necessary
in patients taking NOACs, anticoagulant reversal and a means of measuring reversal may be required for patients who
present with bleeding or require urgent surgery. Prothrombin complex concentrates are pooled plasma products
containing varying amounts of inactive vitamin K-dependent clotting factors in addition to vitamin K-dependent
proteins and can replenish factors in the intrinsic and extrinsic coagulation cascade, reversing an anticoagulant effect.
Only one agent, idarucizumab, has been approved for rapid reversal of dabigatran-induced anticoagulation and one
more agent, andexanet alfa, has been submitted for approval to reverse the anticoagulatory effects of direct and
indirect factor Xa inhibitors.
Conclusions: This review discusses the laboratory tests available for assessing anticoagulation, human models
of bleeding, and the use of current strategies—including prothrombin complex concentrates for reversal of
anticoagulation by NOACs—to manage bleeding in patients.Background
Four nonvitamin K antagonist oral anticoagulants
(NOACs) are approved for the prevention of stroke in
patients with nonvalvular atrial fibrillation (AF) and for
the treatment of venous thromboembolism. These in-
clude the direct thrombin inhibitor dabigatran and the
direct factor Xa (FXa) inhibitors rivaroxaban, apixaban,
and edoxaban [1–4]. In phase 3 clinical testing, all four
NOACs were at least as effective as warfarin in prevent-
ing stroke and systemic embolic events in patients with* Correspondence: jerrold.levy@duke.edu
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stroke compared with warfarin [5–8]. Further, the
NOACs were associated with similar or lower rates of
major or clinically relevant nonmajor bleeding and sig-
nificantly decreased rates of intracranial bleeding com-
pared with warfarin. For the treatment of venous
thromboembolism, the NOACs were noninferior to
standard therapy (including subcutaneous enoxaparin or
heparin followed by warfarin or acenocoumarol), de-
creased major bleeding risk, and decreased or produced
similar clinically relevant nonmajor bleeding risk [9–14].
In a meta-analysis of the NOAC phase 3 trials for
stroke prevention in AF, the NOACs reduced the risk of
stroke or systemic embolic events by 19 % (relative riskle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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primarily through reductions in the risk of hemorrhagic
stroke and reduced rates of all-cause mortality and intra-
cranial hemorrhage relative to warfarin; however, the risk
of gastrointestinal bleeding was increased [15]. Despite
initial reports of a higher prevalence of dabigatran-related
bleeding, analyses of postmarketing data show similar or
lower rates of bleeding compared with warfarin, as re-
ported in phase 3 testing [16, 17]. Similarly, postmarketing
rates of rivaroxaban-associated bleeding were consistent
with phase 3 trial results [18]. Postmarketing results for
apixaban and edoxaban have not yet been published.
Although NOACs reduce the risk of bleeding relative
to warfarin, concerns remain regarding the management
of bleeding related to NOAC use. Bleeding is a compli-
cation for all anticoagulants and concerns regarding
bleeding risk may be a barrier to their prescription des-
pite the known benefits of anticoagulation [19]. Add-
itionally, concomitant medications such as antiplatelet
therapy also increase the bleeding risk for both vitamin
K antagonists (VKAs) and NOACs [20–22]. With short
half-lives ranging from 5 to 17 h [1–4] and pharmaco-
logic activity paralleling plasma concentrations, discon-
tinuation of a NOAC will result in a relatively rapid
return to normal hemostatic function compared with
VKAs, as the NOACs are direct inhibitors of hemostatic
factors. However, no agent has yet been approved for
rapid reversal of anti-FXa NOAC anticoagulation,
although one agent is available for urgent reversal of
dabigatran-associated emergent bleeding [23]. Addition-
ally, no single laboratory test has been established as the
validated, universal measure of the NOACs’ anticoagula-
tion effects, especially for FXa inhibitors. This review
discusses the laboratory tests available for assessing
anticoagulation, human models of bleeding, and the use
of strategies—with a focus on prothrombin complexTable 1 Laboratory assays responsive to NOACs [25, 28, 29]
Dabigatran Rivaroxaban Apix
PT Insensitive at therapeutic
concentrations
Normal PT can exclude
significant drug levels
Inse
aPTT Normal aPTT can exclude
anticoagulation
Insensitive Inse
TT Highly sensitive, must be
diluted
Normal values can exclude
anticoagulation
Insensitive Inse
Anti-FXa Insensitive Sensitive when calibrated;






aPTT activated partial thromboplastin time, FXa direct factor Xa, PT prothrombin timconcentrates (PCCs)—for the reversal of anticoagulation
by NOACs.
Assessment of anticoagulation levels
Unlike VKAs, NOACs do not require routine coagula-
tion monitoring, in part due to predictable pharmaco-
kinetics and pharmacodynamics and fewer drug–drug
and drug–food interactions [24]. Prothrombin time (PT)
and international normalized ratio (INR) are routinely
used to measure VKA anticoagulation levels but INR is
not considered an accurate measure of anticoagula-
tion in patients on NOACs. Unlike VKAs, PT/INR
correction for NOACs does not eliminate the variabil-
ity arising from use of different thromboplastins; this
results in difficulty in standardizing clotting assays for
clinical testing [25, 26].
In the event of emergent bleeding, determination of a
patient’s level of anticoagulation and the ability to meas-
ure the effectiveness of a reversal agent are important.
In addition to determining the management of bleeding,
assessing the presence or absence of anticoagulation can
also eliminate unnecessary and costly actions in attempt-
ing NOAC reversal. Thus, understanding the impact of
NOACs on common laboratory coagulation tests and
the relationship of this impact on clinical coagulation
status is critical. To date, no single routine laboratory
test has been identified to accurately measure the clin-
ical anticoagulation state of patients on NOACs [27], al-
though a number of assays are responsive to NOACs
[25, 28, 29] (Table 1).
Activated partial thromboplastin time (aPTT) can pro-
vide an approximation of the anticoagulation effect of
dabigatran and is a reasonable screening test for the
presence of the direct thrombin inhibitor; however, vari-
ability in results should be expected and no guidance is
provided regarding the clinical relevance of a particularaban Edoxaban Issues related to testing
nsitive Poor sensitivity Highly variable based on reagent;




Highly variable based on reagent;
cannot be standardized across
laboratories
Clinical relevance of recovery
unknown











variability, not widely available.
Preferred assay for rivaroxaban,
apixaban, and edoxaban
e, TT thrombin time
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ing dabigatran include thrombin time (TT), diluted
thrombin time, and ecarin clotting time (ECT) for deter-
mining specific levels of anticoagulation [1].
At therapeutic doses, PT and aPTT are prolonged by
rivaroxaban, apixaban, and edoxaban. However, because
these changes are quite small and variable and
dependent on the thromboplastin employed [28–30],
they are not recommended for routine monitoring of
anticoagulant effects [2–4]. PT and aPTT are less sensi-
tive to apixaban than to rivaroxaban and dabigatran in
head-to-head comparison in platelet-poor plasma [31].
The anti-FXa assay—which assesses ex vivo inhibition of
exogenously added factor Xa—shows a linear correlation
with rivaroxaban, apixaban, and edoxaban concentrations
and may provide a quantitative or semiquantitative meas-
urement when conducted with a NOAC-specific calibrator
[32–35]. Several chromogenic anti-FXa assays demonstrate
a concentration-dependent increase in response to rivarox-
aban, apixaban, and edoxaban [27, 28, 30, 32, 36, 37]. The
anti-FXa reagents vary in dynamic range and there is
significant interlaboratory variability for in vitro as-
sessments [26, 33, 34]. Intrinsic FX activity can be
assayed using a chromogenic method and factor X is
activated by Russell’s viper venom in the presence of
calcium but few data are available on the clinical util-
ity of this assay [35].
Thrombin generation (TG), as measured by endogen-
ous thrombin potential (ETP), is sensitive to NOAC-
related anticoagulation [38–40]; however, this is an ex-
perimental assay that has not been approved for routine
clinical use or been validated in a clinical setting. Sample
collection and preparation can significantly affect the
results of TG assays, making them challenging to imple-
ment. Although several commercial tests for ETP are
available, the lack of standardization within and between
clinical laboratories remains a barrier to greater inclu-
sion in clinical practice [41].
Thromboelastography/rotational thromboelastography
(TEG/ROTEM)-based assays can be affected by dabiga-
tran, rivaroxaban, and apixaban [42, 43]. However, the
results are variable and do not show dose-dependent re-
sponses at clinically relevant concentrations for rivaroxa-
ban and apixaban [43–46]. The TEG test has been
shown to be sensitive to dabigatran-spiked samples
in vitro [47] and has shown a concentration-dependent
response to dabigatran that correlates with ECT and
Hemoclot results [48].
Models of bleeding
Regardless of assay availability, no published studies sug-
gest laboratory tests of hemostasis are predictors of
bleeding risk for NOACs. Thus far, it has been difficult
to establish a reliable human bleeding model to testnovel inhibitors of the coagulation cascade. Reported
models for measuring the effects of antiplatelet agents
are limited by high variability and are not reliably pre-
dictive of individual responses to reversal agents or
bleeding tendency in clinical settings.
Surgicutt (International Technidyne Corporation, Edison,
NJ, USA) and Simplate (Organon Teknika, Durham, NC,
USA) are disposable devices developed for clinical measure-
ment of bleeding times from standardized incisions
[49, 50]. The Surgicutt model is more sensitive to
bleeding time compared with Simplate [49]. However,
the Surgicutt model is associated with high intrasub-
ject variability and limited reproducibility based on a
high degree of interobserver variability [50]. Addition-
ally, this method is relatively insensitive to the effects
of VKAs or the NOACs on clotting time because the
clots formed are highly platelet-dependent (so-called
“white clots”) [21, 51, 52]. The use of bleeding times
to routinely assess platelet function has been replaced
with more sensitive assays using flow cytometry and
specific biomarkers [53].
A limited number of human studies have evaluated
anticoagulant-induced bleeding following punch biopsy.
This method represents a more invasive, and perhaps
less platelet-dependent, model of bleeding and is more
clinically relevant to vasculature injury as encountered
in surgery (or potentially in other wounds) relative to
standardized incisions. This model was initially devel-
oped to detect the effects of warfarin in clinical bleeding
assessments [54] and has subsequently been shown to
be sensitive to the effects of clopidogrel and edoxaban
[40, 55]. The punch biopsy is typically performed on the
back of the leg and removes a uniform cylindrical core
of cutaneous tissue 5 mm in diameter and 4 to 6 mm
deep. Bleeding duration (BD) and bleeding volume
(BV), measured by converting the weight of blood
absorbed on pre-weighed filter paper disks, may be
evaluated [40, 54, 55]. In healthy subjects, VKA antic-
oagulation increased BV and prolonged BD [54].
Administration of recombinant factor VIIa (rFVIIa)
failed to reverse the VKA-induced increase in BV and
prolongation of BD. Further, intersubject variability was
noted in both measures at baseline [54]. The model was
again applied in an assessment of the reversal of clopi-
dogrel by rFVIIa. Clopidogrel prolonged BD and in-
creased BV in healthy volunteers and rFVIIa reduced
the clopidogrel-induced increases in BV to a greater ex-
tent than it reduced BD [55]. However, variability in
baseline BD and BV was again noted and attributed in
part to differences due to inter investigator perform-
ance of the procedure [55].
More recently, edoxaban reversal was evaluated using
a rigorously standardized application of the punch
biopsy method in a phase 1, double-blind, randomized,
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tigators at the study center were extensively trained on
the punch biopsy procedure to reduce variability in per-
forming the procedure. The number of physicians per-
forming the biopsy and assessing BD was limited; for
most subjects, a single physician performed the punch
biopsies at both visits. The efforts to standardize the
punch biopsy method resulted in improved coefficients
of variation for both BD and BV in relation to previous
studies [40, 54, 55]. The intrasubject variability associ-
ated with BD (35 % and 26 % for edoxaban 60 mg and
180 mg, respectively) was lower than that associated
with BV (37.5 % and 35.7 % for edoxaban 60 mg and
180 mg, respectively) [40]. Correlations between BD and
BV with markers of anticoagulation were also assessed.
The lag in TG was significantly correlated with BD
(P = 0.04) and a trend toward correlation between
ETP and BD was also reported (P = 0.07) [40]. Simi-
larly, a trend toward a significant correlation between
BD and PT and aPTT was also noted (P < 0.1). There
was no correlation between anti-FXa or intrinsic FX
activity and BD [40]. The reason for this lack of
correlation is unclear but may reflect the fact that
only two doses of edoxaban were studied and correl-
ation was assessed at a single timepoint. Thus, the
range in exposure may not have been large enough to
establish a clear correlation. Taken together, these
results suggested that both BD and BV were sensitive
to edoxaban dosing and had acceptable variability and
that TG and possibly PT would be appropriate bio-
markers for future studies assessing reversal.
Treatment of hemorrhage
Multiple definitions of bleeding based on different cri-
teria are used in the literature. Generally, minor or mild
bleeding does not pose much risk to the patient. Clinic-
ally relevant major or nonmajor bleeding events require
medical intervention. Major bleeding is defined by the
International Society on Thrombosis and Haemostasis as
fatal bleeding; symptomatic bleeding in a critical area or
organ; and/or bleeding resulting in a fall in hemoglobin
of at least 2 g/dL or bleeding leading to transfusion of 2
or more units of whole blood or blood cells [56]. The
Thrombolysis in Myocardial Infarction Study group def-
inition of major bleeding includes any intracranial bleed-
ing (excluding microhemorrhages <10 mm), clinically
overt signs of hemorrhage with a drop in hemoglobin
≥5 g/dL, and/or fatal bleeding that directly results in
death within 7 days; minor bleeding is defined as any
clinically overt bleeding with a drop in hemoglobin of 3
to <5 g/dL [57, 58].
Reversal of NOACs is only necessary in cases of life-
threatening bleeding or emergency surgery. In instances
of minor bleeding, symptomatic management, such asnasal packing in the case of epistaxis, has been suggested
for patients receiving NOACs [59]. If necessary, delaying
the next dose of anticoagulant or temporarily discon-
tinuing treatment—as the NOACs have relatively short
half-lives—may be sufficient [1–4, 24, 59]. Administering
activated charcoal to reduce NOAC absorption has also
been suggested [24]. In instances of moderate or severe
bleeding, recommendations are primarily supportive and
are similar to those given for VKA-related bleeds;
hemodynamic support to maintain blood pressure, renal
perfusion, and urine output should be provided [60].
Maintenance of hemodynamic support and renal perfu-
sion is important as 80 % of the clearance of an
absorbed dabigatran dose [1] and 66, 50, and 27 % of the
total clearance of rivaroxaban, edoxaban, and apixaban,
respectively, is via the kidneys [2–4]. In the event of
moderate-to-severe bleeding, the European Society of
Cardiology guidelines recommend mechanical com-
pression and volume replacement when appropriate
[61]. Fresh frozen plasma, platelets, red blood cells, and
cryoprecipitate (or fibrinogen concentrates if cryopre-
cipitate is not available) are important for hemostatic
and hemodynamic resuscitation [62, 63]. Notably, the
European Heart Rhythm Association (EHRA) does not
recommend fresh frozen plasma in patients with life-
threatening NOAC-related bleeding and instead sug-
gests PCCs or factor VIII inhibitor bypassing agent
(FEIBA, Baxter, Westlake Village, CA, USA), if available
[64]. However, if the patient is actively hemorrhaging,
then a massive transfusion protocol should be considered
and instituted [64].
Fibrinolysis plays a major role in bleeding and coagu-
lopathy and the use of antifibrinolytics such as tranex-
amic acid can be important additional adjunctive
treatment strategies for major bleeding [65]. Tranexamic
acid interferes with the binding of plasmin to fibrin and
is used to treat bleeding and reduce the need for transfu-
sion in cardiac surgery or trauma [60, 66, 67]. European
Heart Rhythm Association guidelines suggest tranexamic
acid as an adjuvant for non-life-threatening NOAC-
related bleeding based on its use in other bleeding
scenarios; however, animal data suggest that, by itself,
tranexamic acid does not affect NOAC anticoagulation
[68] and clinical data supporting its efficacy in reversal
of NOAC anticoagulation are scarce [64]. Although tran-
examic acid is not expected to reverse anticoagulation
due to edoxaban [4] or other factor Xa inhibitors, it is
an important multimodal consideration for repletion in
critically ill and bleeding patients along with fibrinogen
measurements [69].
Prothrombin complex concentrates
Prothrombin complex concentrates are pooled plasma
products that contain varying amounts of inactive
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vitamin K-dependent proteins. The 3-factor PCCs
(3 F-PCCs) include factors II, IX, and X; 4-factor
PCCs (4 F-PCCs) include factors II, IX, VII, and X
(Table 2) [70]. In addition, different PCC preparations
contain varying levels of heparin and/or anticoagulant
proteins (e.g., proteins C and S) to reduce their prothrom-
botic effects [70]. Both 3 F- and 4 F-PCCs replenish fac-
tors in the intrinsic and extrinsic coagulation cascade
(Fig. 1). The 3 F-PCCs are an approved treatment for fac-
tor IX deficiency in patients with hemophilia B [71]; their
use in anticoagulant reversal is an off-label application in
the US and, until recently, only 3 F-PCCs were available
in the US. A 4 F-PCC was recently approved in the US for
the reversal of VKA anticoagulation in patients with acute
major bleeding [72]. In the European Union, both 3 F-
and 4 F-PCCs are available and 4 F-PCCs are approved
for the reversal of VKAs [73].
PCCs for NOAC reversal
Support for the reversal of the anticoagulant effect of
NOACs in humans with PCCs is based primarily on case
reports, evaluation of ex vivo parameters, and surrogate
biomarker endpoints in healthy volunteers [74]. Thus
far, only one published study has used a bleeding end-
point to assess PCC reversal [40]. At least one registry
trial is underway to assess outcomes in bleeding patients
or those requiring urgent care treated with NOACs and
reversed with PCCs, rFVIIa, and/or hemodialysis, so
these data may be available in the future [75].
Dabigatran, a direct thrombin inhibitor, acts down-
stream of the factors replaced by PCCs (Fig. 1). Previous
studies reported that, by driving TG, PCC administration
could potentially reverse dabigatran anticoagulation. As
reported in ex vivo studies in plasma from dabigatran-Table 2 Variations in PCC compositiona









Factor II 24–38 50 50 31
Factor VII <5 NA 400 16
Factor IX 24–38 60 100 29





Heparin <0.15 IU/IU FIX <1.5 0.5
Table reproduced with permission from Bershad and Suarez [70]
3 F-PCC 3-factor PCC, 4 F-PCC 4-factor PCC, FIX factor IX, IU international units, NA n
aComposition in international units/ml (IU/ml)
bConcentration not specified
cLFFB Laboratoire Français du Fractionnement et des Biotechnologies, Francetreated patients, 4 F-PCC and activated PCC (aka
FEIBA) reversed ETP to near-baseline values at low
doses and dose-dependently increased TG, even at low
doses [76, 77]. However, in vitro or in healthy subjects,
as assessed by prolonged aPTT, ETP lag time, TT, ECT,
and clotting time, a single bolus of 40 or 50 IU/kg 4 F-
PCC was ineffective in reversal of dabigatran 150 mg
twice daily [38, 78]. The use of FEIBA partially reduced
clotting time in vitro [78] and reports suggest that the
concentration of tissue factor present is a key element in
the reversal of dabigatran [79].
Replenishing coagulation factors with 3 F- and 4 F-
PCCs is more likely to affect the reversal of the FXa in-
hibitors than dabigatran. In vitro, apixaban prolongs TG
lag time and reduces peak TG; both rFVIIa and FEIBA
partially restored the prolonged TG lag and significantly
enhanced peak TG. Similarly, 4 F-PCC partially recov-
ered the TG lag but the effect did not reach significance
[80]. At supratherapeutic concentrations of apixaban,
4 F-PCC partially restored ETP and peak TG and short-
ened PT [81]. However, TG lag time was unchanged by
4 F-PCC. rFVIIa had no effect on ETP but it did reduce
TG lag time. FEIBA produced an overcorrection of ETP,
shortened the apixaban-prolonged PT, increased peak
TG, and decreased but did not fully correct TG lag time
or aPTT [81]. In vivo, 4 F-PCC reverses the apixaban-
prolonged PT and increases ETP at 15 minutes following
infusion [82]. Between 6 and 24 h following PCC infu-
sion, ETP returned to and increased above pre-apixaban
levels [82].
Both 3 F- and 4 F-PCCs have also been shown to
affect rivaroxaban TG parameters. Ex vivo, 4 F-PCC
corrected ETP and peak TG modestly; rFVIIa was less
effective in correcting ETP but it did revert rivaroxaban-
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Fig. 1 Sites of action of prothrombin complex concentrates,
nonvitamin K antagonist oral anticoagulants, and warfarin on the
coagulation cascade. Blue boxes indicate factors that are present in
3 F- and 4 F-PCCs; the red box indicates factor present in 4 F-PCCs.
3 F-PCC 3-factor prothrombin complex concentrate, 4 F-PCC 4-factor
prothrombin complex concentrate
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parameters of TG. However, most doses of PCC and
FEIBA tested elevated TG over baseline values [76]. In
vitro, both FEIBA and rFVIIa reversed rivaroxaban-
induced prolonged PT and TG lag time and increased clot-
ting time by roughly 50 % [83]. Peak thrombin was most
strongly reversed by FEIBA [83]. Reversal of ETP by FEIBA
or 4 F-PCC was dependent on rivaroxaban concentration;
FEIBA was more effective in reversal than 4 F-PCC [83].
The use of rFVIIa produced only a partial reversal and TG
was again elevated above baseline values [83]. In vivo, both
3 F-PCC and 4 F-PCC normalized ETP and PT [38, 39],
with faster reversal of prolonged ETP by 3 F-PCC relative
to 4 F-PCC [39]. The reduction of mean PT was greater
with 4 F-PCC relative to 3 F-PCC but 3 F-PCC reversed
TG to a greater degree than 4 F-PCC [39]. It should be
noted that these studies highlight the contribution of
different formulations of PCCs as the PT reduction
can differ in magnitude based upon the 4 F-PCC
chosen [38, 39]. This is attributed to the varying con-
centrations of heparin and anticoagulatory proteins
included in different preparations [39]. Both 3 F- and
4 F-PCC initially prolonged aPTT, which gradually
returned to baseline values [39]. No thromboembolic
events occurred in these studies [38, 39].In pooled plasma, a 1000-ng/mL dose of rFVIIa re-
versed the prolonged PT induced by edoxaban 150 ng/mL
or 300 ng/mL to near control values. Both FEIBA and 4 F-
PCC also significantly reduced PT but did not correct PT
to baseline [84]. Ex vivo, both FEIBA and rFVIIa partially
reversed edoxaban-mediated changes to PT, aPTT, and
anti-FXa at supratherapeutic concentrations of edoxaban
[85]. Neither rFVIIa nor FEIBA significantly reversed the
anticoagulatory effects of edoxaban as measured by intrin-
sic FX activity. Further, no dose response was observed for
rFVIIA or aPCC [85].
In a phase 1 clinical trial, 3 F-PCC was shown to com-
pletely reverse the effects of edoxaban on ETP but failed
to reverse edoxaban-induced prolongation of PT [86]. A
transient dose-dependent increase in prothrombin frag-
ment 1 + 2 was observed, suggesting a possible pro-
coagulant effect, although no thromboembolic events
occurred [86]. However, using the above-described
punch biopsy bleeding model in healthy subjects, 4 F-
PCC produced a dose-dependent reversal of the effects
of edoxaban on both BD and ETP [40]. A 50-IU/kg dose
of 4 F-PCC completely reversed ETP to baseline values
[40]. A similar reduction in BV was noted, while PT was
only partially reversed [40]. Again, no thromboembolic
events occurred [40]. To date, this is the only study to
demonstrate NOAC reversal with a 4 F-PCC with results
correlating to a bleeding endpoint. Further, this study
suggests that ETP may represent an important bio-
marker for edoxaban-related anticoagulation effects [40].
There is a lack of good correlation between PT and
aPTT prolongation and the anticoagulant activity of FXa
inhibitors and, hence, reversal, despite the wide availabil-
ity and ease of these tests. Furthermore, TG (specifically
ETP) may better correlate with anticoagulant activity
and reversal but is an impractical method, particularly in
emergency situations, due to central laboratory capabil-
ities needed for everyday testing. Anti-FXa assays are in
development and correlate best with FXa inhibitor activ-
ity and potentially reversal with specific agents but are
not appropriate for measurement of reversal by PCCs.
Other reversal agents
The dabigatran-specific humanized monoclonal anti-
body fragment idarucizumab was recently approved
for dabigatran-treated patients when reversal of anti-
coagulant effects is needed for emergency surgery or
urgent procedures or in cases of life-threatening or
uncontrolled bleeding [23]. In an interim analysis of a
prospective cohort study, 5 g of idarucizumab rapidly
reversed the anticoagulant effects of dabigatran in
patients who required surgery or experienced life-
threatening bleeding, with no procoagulant effect ob-
served after administration [87]. Among patients with
elevated ECT and dilute TT at baseline, idarucizumab
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gatran in 88 to 98 % of the patients, with only one
thrombotic event reported within 72 h of idarucizu-
mab administration [87]. Following reversal of the
anticoagulant effect, reintroduction of dabigatran may
be initiated as early as 24 h after idarucizumab treat-
ment [88].
Other agents are under investigation. Andexanet
(andexanet alfa, Portola Pharmaceuticals, South San
Francisco, CA, USA), a specific reversal biological agent
that binds to FXa inhibitors and neutralizes the anti-
coagulant effects of both direct and indirect FXa inhibi-
tors, has demonstrated efficacy in preclinical studies and
in reversal of the effects of NOACs on anti-FXa and TG
in clinical studies [89, 90]. Andexanet alfa has been sub-
mitted to the US Food and Drug Administration for ap-
proval [91]. In the ANNEXA-A and ANNEXA-R
(Andexanet Alfa, a Novel Antidote to the Anticoagulation
Effects of FXA Inhibitors Apixaban [ANNEXA-A] and
Rivaroxaban [ANNEXA-R]) randomized, double-blind,
placebo-controlled studies evaluating the ability of andex-
anet to reverse anticoagulation with apixaban and rivarox-
aban in elderly healthy volunteers, reversal of the
anticoagulant activity of apixaban and rivaroxaban (as
measured by the anti-FXa assay) occurred within 2 to
5 minutes after administration of a bolus of andexanet.
This effect persisted for 2 h following administration of a
bolus of andexanet and for 1 to 2 h following administra-
tion of andexanet as a bolus plus a 2-h infusion, without
evidence of serious adverse events or clinical thrombosis
[90]. It is uncertain, however, whether 2 h of reversal is
sufficient for patients at risk of factor Xa inhibitor-
associated acute major bleeding. A longer infusion time
may be required for NOAC patients who require emer-
gency surgery or continue to bleed. Furthermore, the use
of andexanet in combination with tranexamic acid, factor
concentrates, or PCCs has not yet been investigated. A
clinical trial to evaluate the efficacy and safety of an-
dexanet in patients with FXa inhibitor-associated acute
major bleeding is ongoing (ClinicalTrials.gov number
NCT02329327). This study will not include patients re-
quiring emergency surgery or procedural interventions.
Finally, the synthetic small molecule antidote ciraparan-
tag (PER977, Perosphere, Danbury, CT, US) is effective in
reversal of all four NOACs as assessed by a rat tail tran-
section bleeding model as well as in reversal of edoxaban
based on TEG measurements [92, 93]. Ciraparantag has
also been shown to reverse the effects of a single dose of
edoxaban on whole blood clotting time and restore
hemostasis in healthy subjects [94]. A clinical trial to in-
vestigate the safety, tolerability, and effect of ciraparantag
following re-anticoagulation with edoxaban and its ability
to re-reverse edoxaban is ongoing (ClinicalTrials.gov
number NCT02207257).Conclusions
The PCCs are important therapeutic approaches for
hemostatic resuscitation and in surgery and general
trauma. They are widely available for reversal of bleeding
associated with VKA anticoagulation and show promise
for reversal of NOAC-associated bleeding. The wide-
spread acceptance of PCCs for NOAC reversal will be
aided by the development of standardized assays for
NOAC anticoagulation and reversal. However, in a life-
threatening hemorrhage, basic resuscitative principles
should be considered, with hemodynamic and hemostatic
resuscitation of patients. The role of PCCs and other
adjunct factors are important multimodal factors for ther-
apy. Point-of-care anti-FXa tests may be useful tools to
develop for assessing anticoagulation status and specific
reversal agent effects but will not be appropriate for the
measurement of reversal by PCCs.
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